- Home
- MSB vs LRMR Comparison
MSB vs LRMR Comparison
Compare MSB & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSB | LRMR |
|---|---|---|
| Founded | 1961 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 332.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MSB | LRMR |
|---|---|---|
| Price | $33.51 | $3.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.71 |
| AVG Volume (30 Days) | 37.2K | ★ 1.4M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 20.01% | N/A |
| EPS Growth | ★ 425.34 | N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.40 | ★ N/A |
| Revenue Growth | ★ 4.81 | N/A |
| 52 Week Low | $22.55 | $1.61 |
| 52 Week High | $37.00 | $6.48 |
Technical Indicators
Market Signals| Indicator | MSB | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 50.97 |
| Support Level | $32.50 | $3.12 |
| Resistance Level | $35.56 | $4.15 |
| Average True Range (ATR) | 1.71 | 0.25 |
| MACD | 0.23 | 0.05 |
| Stochastic Oscillator | 81.04 | 65.05 |
Price Performance
Historical ComparisonAbout MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.